Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.
Decompensated cirrhosis
Dysbiosis
Inflammation
Portal hypertension
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
23
09
2020
revised:
08
12
2020
accepted:
08
12
2020
entrez:
27
5
2021
pubmed:
28
5
2021
medline:
8
2
2022
Statut:
ppublish
Résumé
The transition from compensated to decompensated cirrhosis results from a complex interplay of predisposing and precipitating factors and represents an inflection point in the probability of a patient surviving. With the progression of cirrhosis, patients accumulate multiple disorders (e.g. altered liver architecture, portal hypertension, local and systemic inflammation, bacterial translocation, gut dysbiosis, kidney vasoconstriction) that predispose them to decompensation. On the background of these factors, precipitating events (e.g. bacterial infection, alcoholic hepatitis, variceal haemorrhage, drug-induced liver injury, flare of liver disease) lead to acute decompensation (ascites, hepatic encephalopathy, variceal bleeding, jaundice) and/or organ failures, which characterise acute-on-chronic liver failure. In this review paper, we will discuss the current hypotheses and latest evidences regarding predisposing and precipitating factors associated with the transition to decompensated liver disease.
Identifiants
pubmed: 34039491
pii: S0168-8278(20)33842-3
doi: 10.1016/j.jhep.2020.12.005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
S36-S48Informations de copyright
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest TG gives advice to Promethera Biosciences, Martin Pharmaceuticals, Goliver therapeutics, and Abbvie and has received grants from Gilead. VS has received speaker’s honoraria/travel expenses from Astellas, Institut Allergosan, Fresenius, MSD, Gilead and research support: Institut Allergosan, Fresenius, Winclove Probiotics. MT received a grant from Novartis. CA and WL have nothing to disclose. Please refer to the accompanying ICMJE disclosure forms for further details.